InFlectis BioScience

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.